

## IN THE SPECIFICATION:

Page 2, Line 11, change "if" to —in—

Page 2, Line 21, change "HMB phosphatidylserine" to —HMB, phosphatidylserine—

Page 11, Line 22, change "(nucleocapsid inhibitors) While" to —(nucleocapsid inhibitors).

While—

Page 11, Line 14, change "BCH-10652" to BCH 10652 (2'-deoxy-3'-oxa-4'-thiocytidine) ~~A~~

Page 11, Line 14, change "FTC-TBD" to FTC (the 5'-fluoro congener of 3TC)—

Page 11, Line 15, change "MKC-482/TBD" to MKC-442 (a new non-nucleoside reverse

transcriptase inhibitor)

Page 11, Line 16, change "PMPA/bis-poc PMPA" to Bis-POC-PMPA (the deoxyadenosine

monophosphate analogue of 9-[2-(R)-(phosphonomethoxy)propyl]adenine)

Page 19, Line 21, change "suspention" to —suspension—

Page 21, table, change "ritonair" to —ritonavir—

Page 22, table, change "ritonair" to —ritonavir—

## IN THE CLAIMS:

Kindly rewrite Claims 1, 2, 6, 7, 10, 11 and 15 as follows: